pipeline-prospector-insert-v1
X

Find Clinical Drug Pipelines for Trauma (Emergency, Injury, Surgery)

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Study Phase filter
    Country filter
      News Type filter
        Company filter
          Product Type filter
            refresh

            Product Type

            Development Status

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ronopterin

            Therapeutic Area: Trauma (Emergency, Injury, Surgery)

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 29, 2020

            Details:

            NOSTRA III is a 220 patient Phase III clinical trial assessing efficacy and safety of Ronopternin (VAS203) for the treatment of moderately to severely injured closed head traumatic brain injuries.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PRV-002

            Therapeutic Area: Trauma (Emergency, Injury, Surgery)

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 29, 2020

            Details:

            Prevacus, has completed GMP certification of API for their lead compound for treating concussion and is now preparing the final nano-formulation for nasal application to initiate its first human trials.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Nangibotide

            Therapeutic Area: Trauma (Emergency, Injury, Surgery)

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Roche Diagnostics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 21, 2020

            Details:

            Inotrem entered a worldwide licensing agreement with Roche Diagnostics for the commercialization of a mechanism-based companion diagnostic test using a soluble plasma protein.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PB2452

            Therapeutic Area: Trauma (Emergency, Injury, Surgery)

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: SFJ Pharmaceuticals

            Deal Size: $120.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration January 10, 2020

            Details:

            The collaboration with SFJ provides PhaseBio with substantial funding to continue the rapid advancement of lead program, PB2452.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): rhNELL-1

            Therapeutic Area: Trauma (Emergency, Injury, Surgery)

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 08, 2020

            Details:

            Bone Biologics has completed a preclinical study, which shows its rhNELL-1 growth factor effectively promotes bone formation in a phylogenetically advanced spine model.

            NorthShore University HealthSystem

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dantrolene Sodium

            Therapeutic Area: Trauma (Emergency, Injury, Surgery)

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Eagle Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement January 06, 2020

            Details:

            Under the terms of the agreement, NorthShore University HealthSystem will study Eagle’s RYANODEX® (dantrolene sodium) for traumatic brain injury (TBI) in animal models.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Acetylcysteine Sodium

            Therapeutic Area: Trauma (Emergency, Injury, Surgery)

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: ATAI Life Sciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership January 06, 2020

            Details:

            The partners will develop a short-term treatment which includes intranasal delivery of low doses of N-acetylcysteine for mild Traumatic Brain Injury (mTBI) or concussion.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bromelain

            Therapeutic Area: Trauma (Emergency, Injury, Surgery)

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: MediWound

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement January 02, 2020

            Details:

            The agreement is part of MediWound's global commercialization strategy that will expand the medical and commercial potential of NexoBrid to treat skin burns.